These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 29259050)

  • 1. Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate.
    Matsuno H; Tomomitsu M; Hagino A; Shin S; Lee J; Song YW
    Ann Rheum Dis; 2018 Apr; 77(4):488-494. PubMed ID: 29259050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study.
    Park MC; Matsuno H; Kim J; Park SH; Lee SH; Park YB; Lee YJ; Lee SI; Park W; Sheen DH; Choe JY; Choi CB; Hong SJ; Suh CH; Lee SS; Cha HS; Yoo B; Hur JW; Kim GT; Yoo WH; Baek HJ; Shin K; Shim SC; Yang HI; Kim HA; Park KS; Choi IA; Lee J; Tomomitsu M; Shin S; Lee J; Song YW
    Arthritis Res Ther; 2019 May; 21(1):122. PubMed ID: 31113455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study.
    Bae SC; Kim J; Choe JY; Park W; Lee SH; Park YB; Shim SC; Lee SS; Sung YK; Choi CB; Lee SR; Park H; Ahn Y;
    Ann Rheum Dis; 2017 Jan; 76(1):65-71. PubMed ID: 26905864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study.
    Jaworski J; Matucci-Cerinic M; Schulze-Koops H; Buch MH; Kucharz EJ; Allanore Y; Kavanaugh A; Young P; Babic G
    Arthritis Res Ther; 2019 May; 21(1):130. PubMed ID: 31138316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.
    Emery P; Vencovský J; Sylwestrzak A; Leszczyński P; Porawska W; Baranauskaite A; Tseluyko V; Zhdan VM; Stasiuk B; Milasiene R; Barrera Rodriguez AA; Cheong SY; Ghil J
    Ann Rheum Dis; 2017 Jan; 76(1):51-57. PubMed ID: 26150601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LBEC0101, an etanercept biosimilar for the treatment of rheumatoid arthritis.
    Song YW; Park YB; Kim J
    Expert Opin Biol Ther; 2021 Jan; 21(1):1-8. PubMed ID: 31801395
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of safety and effectiveness between etanercept biosimilar LBEC0101 and reference in patients with rheumatoid arthritis in real-world data using the KURAMA cohort.
    Kawakami T; Masui S; Onishi A; Onizawa H; Fujii T; Murakami K; Murata K; Tanaka M; Shimada T; Nakagawa S; Matsuda S; Morinobu A; Terada T; Yonezawa A
    Mod Rheumatol; 2024 Oct; 34(6):1135-1141. PubMed ID: 38516944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.
    Choe JY; Prodanovic N; Niebrzydowski J; Staykov I; Dokoupilova E; Baranauskaite A; Yatsyshyn R; Mekic M; Porawska W; Ciferska H; Jedrychowicz-Rosiak K; Zielinska A; Choi J; Rho YH; Smolen JS
    Ann Rheum Dis; 2017 Jan; 76(1):58-64. PubMed ID: 26318384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis.
    Takeuchi T; Miyasaka N; Zang C; Alvarez D; Fletcher T; Wajdula J; Yuasa H; Vlahos B
    Mod Rheumatol; 2013 Jul; 23(4):623-33. PubMed ID: 23011358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study.
    van Riel PL; Taggart AJ; Sany J; Gaubitz M; Nab HW; Pedersen R; Freundlich B; MacPeek D;
    Ann Rheum Dis; 2006 Nov; 65(11):1478-83. PubMed ID: 16464988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
    Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
    J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis.
    Emery P; Vencovský J; Sylwestrzak A; Leszczynski P; Porawska W; Baranauskaite A; Tseluyko V; Zhdan VM; Stasiuk B; Milasiene R; Barrera Rodriguez AA; Cheong SY; Ghil J
    Rheumatology (Oxford); 2017 Dec; 56(12):2093-2101. PubMed ID: 28968793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension.
    Genovese MC; Glover J; Greenwald M; Porawska W; El Khouri EC; Dokoupilova E; Vargas JI; Stanislavchuk M; Kellner H; Baranova E; Matsunaga N; Alten R
    Arthritis Res Ther; 2019 Dec; 21(1):281. PubMed ID: 31831079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.
    Cohen SB; Alten R; Kameda H; Hala T; Radominski SC; Rehman MI; Palaparthy R; Schumacher K; Schmitt S; Hua SY; Ianos C; Sewell KL
    Arthritis Res Ther; 2018 Jul; 20(1):155. PubMed ID: 30053896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study.
    Cohen SB; Alonso-Ruiz A; Klimiuk PA; Lee EC; Peter N; Sonderegger I; Assudani D
    Ann Rheum Dis; 2018 Jun; 77(6):914-921. PubMed ID: 29514803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial.
    Nam JL; Villeneuve E; Hensor EM; Wakefield RJ; Conaghan PG; Green MJ; Gough A; Quinn M; Reece R; Cox SR; Buch MH; van der Heijde DM; Emery P
    Ann Rheum Dis; 2014 Jun; 73(6):1027-36. PubMed ID: 24618266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis.
    Pope JE; Haraoui B; Thorne JC; Vieira A; Poulin-Costello M; Keystone EC
    Ann Rheum Dis; 2014 Dec; 73(12):2144-51. PubMed ID: 23979914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.
    Yoo DH; Hrycaj P; Miranda P; Ramiterre E; Piotrowski M; Shevchuk S; Kovalenko V; Prodanovic N; Abello-Banfi M; Gutierrez-Ureña S; Morales-Olazabal L; Tee M; Jimenez R; Zamani O; Lee SJ; Kim H; Park W; Müller-Ladner U
    Ann Rheum Dis; 2013 Oct; 72(10):1613-20. PubMed ID: 23687260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy and safety of LBAL, a candidate adalimumab biosimilar, and adalimumab reference product in patients with active rheumatoid arthritis inadequately responding to methotrexate: a 52-week phase III randomised study.
    Matsuno H; Kang YM; Okada M; Lee SI; Park SH; Sheen DH; Sato M; Hagino A; Lee J; Shin S; Song YW
    Clin Exp Rheumatol; 2022 May; 40(5):1025-1033. PubMed ID: 34251303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study.
    Cohen S; Genovese MC; Choy E; Perez-Ruiz F; Matsumoto A; Pavelka K; Pablos JL; Rizzo W; Hrycaj P; Zhang N; Shergy W; Kaur P
    Ann Rheum Dis; 2017 Oct; 76(10):1679-1687. PubMed ID: 28584187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.